Positive Trial Results for Rezzayo Antifungal Drug
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Source: stocktwits
- Trial Results: Rezzayo demonstrated comparable efficacy to standard antimicrobial regimens in reducing invasive fungal infection incidence, with a 90-day fungal-free survival rate of 60.7% versus 59.0% in the standard group, indicating its potential value in high-risk patient populations.
- Market Opportunity: CorMedix estimates that the potential U.S. market opportunity for Rezzayo in preventative care exceeds $2 billion, highlighting the drug's significance in treating high-risk blood cancer patients.
- Safety and Tolerability: The trial results indicated that Rezzayo was well tolerated, with a favorable benefit/risk profile in the patient population, and fewer drug interactions and discontinuations due to toxicity, enhancing its attractiveness for clinical use.
- FDA Application Plans: CorMedix plans to meet with the U.S. FDA in the coming months and expects to file an application for Rezzayo in the second half of 2026, further advancing the drug's path to market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRMD
Wall Street analysts forecast CRMD stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.670
Low
13.00
Averages
13.67
High
15.00
Current: 8.670
Low
13.00
Averages
13.67
High
15.00
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CorMedix Wins Patent Case Affirmation
- Patent Victory: The U.S. Court of Appeals affirmed a favorable ruling for CorMedix's subsidiary Melinta Therapeutics, validating the patents for MINOCIN for Injection and confirming infringement by Nexus Pharmaceuticals, thereby securing CorMedix's market exclusivity.
- Injunction Upheld: The court also upheld a permanent injunction against Nexus, preventing it from marketing its generic minocycline product until patent expiration, which will protect CorMedix's market share and enhance its competitive position in the antibiotic sector.
- Positive Market Reaction: CRMD has traded between $6.13 and $17.43 over the past year, currently priced at $8.45, reflecting a 1.14% increase, indicating market confidence in the company's intellectual property protection and optimism for future growth.
- Strategic Implications: CEO Joseph Todisco emphasized that the ruling validates the strength of the company's intellectual property portfolio and highlights the importance of protecting pharmaceutical innovation, further solidifying CorMedix's market position in therapies for critically ill patients.
See More
CorMedix Patent Validated by Federal Circuit Court Ruling
- Patent Validity Affirmed: The U.S. Federal Circuit Court upheld the validity of CorMedix's MINOCIN® Injection patents and ruled that Nexus Pharmaceuticals infringed these patents, demonstrating CorMedix's strong intellectual property protection capabilities.
- Court Ruling Impact: Following a four-day trial in 2023, the court ruled in favor of CorMedix's wholly-owned subsidiary Melinta Therapeutics on all patent infringement and validity claims, ensuring the company's competitive advantage in the market.
- Sales Ban Issued: The court also affirmed a permanent injunction against Nexus, barring it from marketing its generic product prior to patent expiration, further solidifying CorMedix's market position and product exclusivity.
- Protection of Innovative Drugs: CorMedix CEO Joseph Todisco stated that this ruling underscores the importance of protecting pharmaceutical innovation, and the company will continue to defend its intellectual property to support future product development and market expansion.
See More
CorMedix to Participate in Two Major Healthcare Conferences
- Investor Meeting Schedule: CorMedix Therapeutics will participate in the RBC Capital Markets Global Healthcare Conference in New York on May 19-20, 2026, showcasing its latest advancements in the biopharmaceutical sector, which is expected to attract significant investor interest.
- Timing and Format: The management team is scheduled to conduct a fireside chat on May 20 at 11:00 AM EDT during the RBC conference, aiming to delve into the company's strategic direction and market opportunities.
- Subsequent Conference Engagement: Following this, CorMedix will also present at the Jefferies Global Healthcare Conference from June 2-4, 2026, further expanding its influence among investors and highlighting the market potential of its products.
- Company Overview: CorMedix focuses on developing and commercializing therapeutic products for life-threatening conditions, with a medical and commercial infrastructure deployed in hospitals, clinics, and infusion centers across the U.S., aiming to enhance its market position in the healthcare industry.
See More
CorMedix Q1 2026 Earnings Call Insights
- Strong Financial Performance: CorMedix reported Q1 2026 net revenue of $127.4 million, a significant increase from $39.1 million in Q1 2025, demonstrating robust demand and market penetration for its core product, DefenCath.
- Adjusted EBITDA Growth: The adjusted EBITDA for the first quarter reached $70 million, indicating effective cost control measures that are expected to further enhance overall profitability moving forward.
- Upgraded Full-Year Guidance: The company raised its 2026 net revenue guidance from a range of $300 million to $320 million to a new range of $325 million to $345 million, reflecting management's confidence in future performance, particularly in DefenCath sales growth.
- Investment in R&D and Workforce: CorMedix anticipates adding 15 to 20 new employees in the second half of the year to support its commercial and medical divisions, indicating a strategic investment in future growth, despite an expected increase in operating expenses to $145 million to $160 million.
See More
CorMedix Reports Strong Q1 Earnings, Raises 2026 Revenue Guidance
- Revenue Surge: CorMedix reported Q1 revenue of $127.4 million, significantly exceeding Wall Street's expectation of $105 million, primarily driven by DefenCath sales generating $97.5 million, indicating strong market demand and product acceptance.
- Earnings Beat: The company achieved earnings of $0.43 per share, surpassing analyst estimates of $0.37, reflecting significant improvements in cost control and operational efficiency, which further bolstered investor confidence.
- 2026 Outlook Raised: CorMedix raised its full-year 2026 net revenue guidance to between $325 million and $345 million, up from the previous forecast of $300 million to $320 million, demonstrating optimism about future growth prospects.
- Stock Price Rally: Following the earnings report, CorMedix shares surged over 18%, reaching their highest level since January 2026, reflecting strong market confidence in the company's outlook and positive investor sentiment.
See More
CorMedix Q1 Earnings Exceed Expectations
- Strong Performance: CorMedix reported Q1 GAAP EPS of $0.43, beating expectations by $0.06, indicating a significant improvement in profitability and enhancing the company's competitive position in the market.
- Substantial Revenue Growth: The company achieved Q1 revenue of $127.4 million, a remarkable 226% increase year-over-year, surpassing market expectations by $22.44 million, demonstrating strong product demand and expanding market share.
- Adjusted EBITDA Success: Q1 adjusted EBITDA reached $70 million, showcasing the company's success in cost control and operational efficiency, further boosting investor confidence in its future growth prospects.
- 2026 Guidance Raised: CorMedix raised its 2026 net revenue guidance to a range of $325 to $345 million and adjusted EBITDA guidance to $115 to $135 million, reflecting an optimistic outlook for future performance that is likely to attract more investor interest.
See More
CorMedix Wins Patent Case Affirmation
- Patent Victory: The U.S. Court of Appeals affirmed a favorable ruling for CorMedix's subsidiary Melinta Therapeutics, validating the patents for MINOCIN for Injection and confirming infringement by Nexus Pharmaceuticals, thereby securing CorMedix's market exclusivity.
- Injunction Upheld: The court also upheld a permanent injunction against Nexus, preventing it from marketing its generic minocycline product until patent expiration, which will protect CorMedix's market share and enhance its competitive position in the antibiotic sector.
- Positive Market Reaction: CRMD has traded between $6.13 and $17.43 over the past year, currently priced at $8.45, reflecting a 1.14% increase, indicating market confidence in the company's intellectual property protection and optimism for future growth.
- Strategic Implications: CEO Joseph Todisco emphasized that the ruling validates the strength of the company's intellectual property portfolio and highlights the importance of protecting pharmaceutical innovation, further solidifying CorMedix's market position in therapies for critically ill patients.
See More
CorMedix Patent Validated by Federal Circuit Court Ruling
- Patent Validity Affirmed: The U.S. Federal Circuit Court upheld the validity of CorMedix's MINOCIN® Injection patents and ruled that Nexus Pharmaceuticals infringed these patents, demonstrating CorMedix's strong intellectual property protection capabilities.
- Court Ruling Impact: Following a four-day trial in 2023, the court ruled in favor of CorMedix's wholly-owned subsidiary Melinta Therapeutics on all patent infringement and validity claims, ensuring the company's competitive advantage in the market.
- Sales Ban Issued: The court also affirmed a permanent injunction against Nexus, barring it from marketing its generic product prior to patent expiration, further solidifying CorMedix's market position and product exclusivity.
- Protection of Innovative Drugs: CorMedix CEO Joseph Todisco stated that this ruling underscores the importance of protecting pharmaceutical innovation, and the company will continue to defend its intellectual property to support future product development and market expansion.
See More
CorMedix to Participate in Two Major Healthcare Conferences
- Investor Meeting Schedule: CorMedix Therapeutics will participate in the RBC Capital Markets Global Healthcare Conference in New York on May 19-20, 2026, showcasing its latest advancements in the biopharmaceutical sector, which is expected to attract significant investor interest.
- Timing and Format: The management team is scheduled to conduct a fireside chat on May 20 at 11:00 AM EDT during the RBC conference, aiming to delve into the company's strategic direction and market opportunities.
- Subsequent Conference Engagement: Following this, CorMedix will also present at the Jefferies Global Healthcare Conference from June 2-4, 2026, further expanding its influence among investors and highlighting the market potential of its products.
- Company Overview: CorMedix focuses on developing and commercializing therapeutic products for life-threatening conditions, with a medical and commercial infrastructure deployed in hospitals, clinics, and infusion centers across the U.S., aiming to enhance its market position in the healthcare industry.
See More
CorMedix Q1 2026 Earnings Call Insights
- Strong Financial Performance: CorMedix reported Q1 2026 net revenue of $127.4 million, a significant increase from $39.1 million in Q1 2025, demonstrating robust demand and market penetration for its core product, DefenCath.
- Adjusted EBITDA Growth: The adjusted EBITDA for the first quarter reached $70 million, indicating effective cost control measures that are expected to further enhance overall profitability moving forward.
- Upgraded Full-Year Guidance: The company raised its 2026 net revenue guidance from a range of $300 million to $320 million to a new range of $325 million to $345 million, reflecting management's confidence in future performance, particularly in DefenCath sales growth.
- Investment in R&D and Workforce: CorMedix anticipates adding 15 to 20 new employees in the second half of the year to support its commercial and medical divisions, indicating a strategic investment in future growth, despite an expected increase in operating expenses to $145 million to $160 million.
See More
CorMedix Reports Strong Q1 Earnings, Raises 2026 Revenue Guidance
- Revenue Surge: CorMedix reported Q1 revenue of $127.4 million, significantly exceeding Wall Street's expectation of $105 million, primarily driven by DefenCath sales generating $97.5 million, indicating strong market demand and product acceptance.
- Earnings Beat: The company achieved earnings of $0.43 per share, surpassing analyst estimates of $0.37, reflecting significant improvements in cost control and operational efficiency, which further bolstered investor confidence.
- 2026 Outlook Raised: CorMedix raised its full-year 2026 net revenue guidance to between $325 million and $345 million, up from the previous forecast of $300 million to $320 million, demonstrating optimism about future growth prospects.
- Stock Price Rally: Following the earnings report, CorMedix shares surged over 18%, reaching their highest level since January 2026, reflecting strong market confidence in the company's outlook and positive investor sentiment.
See More
CorMedix Q1 Earnings Exceed Expectations
- Strong Performance: CorMedix reported Q1 GAAP EPS of $0.43, beating expectations by $0.06, indicating a significant improvement in profitability and enhancing the company's competitive position in the market.
- Substantial Revenue Growth: The company achieved Q1 revenue of $127.4 million, a remarkable 226% increase year-over-year, surpassing market expectations by $22.44 million, demonstrating strong product demand and expanding market share.
- Adjusted EBITDA Success: Q1 adjusted EBITDA reached $70 million, showcasing the company's success in cost control and operational efficiency, further boosting investor confidence in its future growth prospects.
- 2026 Guidance Raised: CorMedix raised its 2026 net revenue guidance to a range of $325 to $345 million and adjusted EBITDA guidance to $115 to $135 million, reflecting an optimistic outlook for future performance that is likely to attract more investor interest.
See More
